BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 12110259)

  • 1. Neuraminidase inhibitors as antivirals.
    Colman PM
    Vaccine; 2002 May; 20 Suppl 2():S55-8. PubMed ID: 12110259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidase.
    Watson KG; Cameron R; Fenton RJ; Gower D; Hamilton S; Jin B; Krippner GY; Luttick A; McConnell D; MacDonald SJ; Mason AM; Nguyen V; Tucker SP; Wu WY
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1589-92. PubMed ID: 15006410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surveillance for neuraminidase inhibitor resistance in human influenza viruses from Australia.
    Hurt AC; Barr IG; Durrant CJ; Shaw RP; Sjogren HM; Hampson AW
    Commun Dis Intell Q Rep; 2003; 27(4):542-7. PubMed ID: 15508516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zanamivir. A potent and selective inhibitor of influenza A and B viruses.
    Aoki FY; Hayden FG
    Clin Pharmacokinet; 1999; 36 Suppl 1():v-ix. PubMed ID: 10429834
    [No Abstract]   [Full Text] [Related]  

  • 5. Zanamivir: from drug design to the clinic.
    Elliott M
    Philos Trans R Soc Lond B Biol Sci; 2001 Dec; 356(1416):1885-93. PubMed ID: 11779388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors.
    McSharry JJ; McDonough AC; Olson BA; Drusano GL
    Clin Diagn Lab Immunol; 2004 Jan; 11(1):21-8. PubMed ID: 14715540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals.
    Leneva IA; Goloubeva O; Fenton RJ; Tisdale M; Webster RG
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1216-24. PubMed ID: 11257037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675.
    Molla A; Kati W; Carrick R; Steffy K; Shi Y; Montgomery D; Gusick N; Stoll VS; Stewart KD; Ng TI; Maring C; Kempf DJ; Kohlbrenner W
    J Virol; 2002 Jun; 76(11):5380-6. PubMed ID: 11991966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides.
    Smith PW; Sollis SL; Howes PD; Cherry PC; Starkey ID; Cobley KN; Weston H; Scicinski J; Merritt A; Whittington A; Wyatt P; Taylor N; Green D; Bethell R; Madar S; Fenton RJ; Morley PJ; Pateman T; Beresford A
    J Med Chem; 1998 Mar; 41(6):787-97. PubMed ID: 9526555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus.
    Abed Y; Goyette N; Boivin G
    Antivir Ther; 2004 Aug; 9(4):577-81. PubMed ID: 15456089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and anti-influenza virus activity of 7-O-alkylated derivatives related to zanamivir.
    Honda T; Masuda T; Yoshida S; Arai M; Kaneko S; Yamashita M
    Bioorg Med Chem Lett; 2002 Aug; 12(15):1925-8. PubMed ID: 12113810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en.
    Staschke KA; Colacino JM; Baxter AJ; Air GM; Bansal A; Hornback WJ; Munroe JE; Laver WG
    Virology; 1995 Dec; 214(2):642-6. PubMed ID: 8553569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and influenza virus sialidase inhibitory activity of analogues of 4-Guanidino-Neu5Ac2en (Zanamivir) modified in the glycerol side-chain.
    Andrews DM; Cherry PC; Humber DC; Jones PS; Keeling SP; Martin PF; Shaw CD; Swanson S
    Eur J Med Chem; 1999; 34(7-8):563-74. PubMed ID: 11278042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors.
    Boivin G; Goyette N
    Antiviral Res; 2002 Jun; 54(3):143-7. PubMed ID: 12062387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in in vitro susceptibility of influenza A H3N2 viruses to a neuraminidase inhibitor drug during evolution in the human host.
    Thompson CI; Barclay WS; Zambon MC
    J Antimicrob Chemother; 2004 May; 53(5):759-65. PubMed ID: 15028666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.
    Gubareva LV; Webster RG; Hayden FG
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3403-8. PubMed ID: 11709315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selection of influenza A and B viruses for resistance to 4-guanidino-Neu5Ac2en in cell culture.
    Colacino JM; Laver WG; Air GM
    J Infect Dis; 1997 Aug; 176 Suppl 1():S66-8. PubMed ID: 9240698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utilization of the embryonated egg for in vivo evaluation of the anti-influenza virus activity of neuraminidase inhibitors.
    Sauerbrei A; Haertl A; Brandstaedt A; Schmidtke M; Wutzler P
    Med Microbiol Immunol; 2006 Jun; 195(2):65-71. PubMed ID: 16059699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relenza.
    McCauley J
    Curr Biol; 1999 Nov; 9(21):R796. PubMed ID: 10556097
    [No Abstract]   [Full Text] [Related]  

  • 20. Neuraminidase inhibitors for influenza.
    Moscona A
    N Engl J Med; 2005 Sep; 353(13):1363-73. PubMed ID: 16192481
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.